Your email has been successfully added to our mailing list.

×
4.00160064025246E-05 0.00192076830732289 0.00112044817927171 0.000960384153661501 -0.00104041616646655 0.00622248899559827 0.000500200080032013 -0.00360144057623051
Stock impact report

Regeneron's R&D approach scores dual wins against Alexion's Ultomiris and in lymphoma [Yahoo! Finance]

Alnylam Pharmaceuticals, Inc. (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
Company Research Source: Yahoo! Finance
outperforming Alexion's Ultomiris in a head-to-head trial for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and its bispecific antibody Ordspono achieving a complete response in all 12 previously untreated patients with follicular lymphoma, setting it up for a potential best-in-class performance in the crowded lymphoma market. This story was originally published on PharmaVoice . To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter Regeneron left the American Society for Hematology meeting in San Diego this week with a pair of trial aces, notching a head-to-head win against a rare disease blockbuster and a potential best-in-class performance in the crowded lymphoma market. For Dr. L. Andres Sirulnik, senior vice president of translational and clinical sciences in hematology, the achievements come down to the company's long-haul scientific efforts . Regeneron, despite playing catch-up in several disease markets, has a thriving pipel Show less Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALNY alerts
Opt-in for
ALNY alerts

from News Quantified
Opt-in for
ALNY alerts

from News Quantified